Secondary analysis of ATTRibute-CM: in 611 adults with transthyretin amyloid cardiomyopathy, acoramidis vs placebo improved KCCQ-OS health status at 30 months (LSM difference 9.9; 95% CI 6.0-13.9); post hoc, 47% vs 30% were alive and not worse.
Secondary analysisn = 611
Sherrod et al. Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial